An overview of benefit/risk of disease modifying treatment of rheumatoid arthritis as of today Harold E Paulus Ann Rheum Dis 1982; 41 (Suppl 1 ): 26-29. doi:10.1136/ard.41.Suppl_1.26 [Abstract] [PDF] [Request Permissions]
	Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis H A Isomäki, T Hakulinen, and U Joutsenlahti Ann Rheum Dis 1982; 41 (Suppl 1 ): 34-36. doi:10.1136/ard.41.Suppl_1.34 [Abstract] [PDF] [Request Permissions]
	Discussion Ann Rheum Dis 1982; 41 (Suppl 1 ): 48-52. doi:10.1136/ard.41.Suppl_1.48 [PDF] [Request Permissions]
	Conclusions Colin G Barnes and John L Decker Ann Rheum Dis 1982; 41 (Suppl 1 ): 53. doi:10.1136/ard.41.Suppl_1.53 [PDF] [Request Permissions]
	References Ann Rheum Dis 1982; 41 (Suppl 1 ): 54-60. doi:10.1136/ard.41.Suppl_1.54 [PDF] [Request Permissions]

	Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective. Ann Rheum Dis 1982; 41 (Suppl 1 ): 1-60. doi:10.1136/ard.41.Suppl_1.1-a [PDF] [Request Permissions]
	The choice of, and the decision to apply, disease modifying drugs. C G Barnes Ann Rheum Dis 1982; 41 (Suppl 1 ): 1-2. doi:10.1136/ard.41.Suppl_1.1-b [PDF] [Request Permissions]
	Immunosuppression and the rheumatic diseases. A M Denman Ann Rheum Dis 1982; 41 (Suppl 1 ): 3-8. doi:10.1136/ard.41.Suppl_1.3 [Abstract] [PDF] [Request Permissions]
	Differences among immunosuppressive agents. G H Hitchings Ann Rheum Dis 1982; 41 (Suppl 1 ): 9-11. doi:10.1136/ard.41.Suppl_1.9 [Abstract] [PDF] [Request Permissions]
	The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. B L Hazleman Ann Rheum Dis 1982; 41 (Suppl 1 ): 12-17. doi:10.1136/ard.41.Suppl_1.12 [Abstract] [PDF] [Request Permissions]
	Long-term effects of azathioprine in rheumatoid arthritis. M B Urowitz, H A Smythe, T Able, C S Norman, and C Travis Ann Rheum Dis 1982; 41 (Suppl 1 ): 18-22. doi:10.1136/ard.41.Suppl_1.18 [Abstract] [PDF] [Request Permissions]
	Interim observations on benefit/risk of azathioprine versus D-penicillamine in the treatment of rheumatoid arthritis. J R Ward and H J Williams Ann Rheum Dis 1982; 41 (Suppl 1 ): 23-25. doi:10.1136/ard.41.Suppl_1.23 [PDF] [Request Permissions]
	EULAR register of patients on immunosuppressive drugs. A Kay Ann Rheum Dis 1982; 41 (Suppl 1 ): 30-31. doi:10.1136/ard.41.Suppl_1.30 [PDF] [Request Permissions]
	The incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis. A B Kirsner, S J Farber, R P Sheon, and R I Finkel Ann Rheum Dis 1982; 41 (Suppl 1 ): 32-33. doi:10.1136/ard.41.Suppl_1.32 [Abstract] [PDF] [Request Permissions]
	Side-effects of azathioprine treatment in rheumatoid arthritis: analysis of 10 years of experience. F Speerstra, A M Boerbooms, L B van de Putte, H J van Beusekom, M W Kruijsen, and J P Vandenbroucke Ann Rheum Dis 1982; 41 (Suppl 1 ): 37-39. doi:10.1136/ard.41.Suppl_1.37 [Abstract] [PDF] [Request Permissions]
	Compliance and long-term effect of azathioprine in 65 rheumatoid arthritis cases. P van Wanghe and J Dequeker Ann Rheum Dis 1982; 41 (Suppl 1 ): 40-43. doi:10.1136/ard.41.Suppl_1.40 [Abstract] [PDF] [Request Permissions]
	Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities. J K Whisnant and J Pelkey Ann Rheum Dis 1982; 41 (Suppl 1 ): 44-47. doi:10.1136/ard.41.Suppl_1.44 [Abstract] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.